Neoadjuvant chemotherapy for breast cancer: an evaluation of its efficacy and research progress

Abstract

Neoadjuvant chemotherapy (NAC) for breast cancer is widely used in the clinical setting to improve the chance of surgery, breast conservation and quality of life for patients with advanced breast cancer. A more accurate efficacy evaluation system is important for the decision of surgery timing and chemotherapy regimen implementation. However, current methods, encompassing imaging techniques such as ultrasound and MRI, along with non-imaging approaches like pathological evaluations, often fall short in accurately depicting the therapeutic effects of NAC. Imaging techniques are subjective and only reflect macroscopic morphological changes, while pathological evaluation is the gold standard for efficacy assessment but has the disadvantage of delayed results. In an effort to identify assessment methods that align more closely with real-world clinical demands, this paper provides an in-depth exploration of the principles and clinical applications of various assessment approaches in the neoadjuvant chemotherapy process.

Construction and Validation of a Novel Model for Guiding Targeted Combined Immunotherapy in Advanced Hepatocellular Carcinoma

“…Studies have con rmed that changes in tumor volume and diameter, as observed through MRI, are among the most accurate indicators of pathological response following treatment. This is especially true for breast cancer NAC, where reducing tumor volume has been identi ed as the most reliable indicator of pathological response, followed closely by changes in tumor diameter [17] .…”